Daily physical activity and related risk factors in COPD by Albarrati, Ali M. et al.
RESEARCH ARTICLE Open Access
Daily physical activity and related risk
factors in COPD
Ali M. Albarrati1,2*, Nichola S. Gale1, Maggie M. Munnery3, John R. Cockcroft3 and Dennis J. Shale3
Abstract
Background: Factors associated with reduced daily physical activity (DPA) in patients with COPD are still
controversial. Physical inactivity in COPD increases risk of cardiovascular disease, frequent exacerbations, reduced
health status, and increased symptoms. We hypothesised that reduced DPA in patients with COPD is independent
of traditional risk factors including age and spirometry.
Methods: In this cross-sectional study, DPA (over 7 days) was assessed on 88 community stable patients with COPD
and 40 controls free from cardiorespiratory disease. Spirometry, body composition, number of exacerbations,
handgrip strength (HGS), modified Medical Research Council (mMRC), arterial stiffness, 6-min walking distance
(6MWD) and BODE index were also determined. Frequent exacerbation was defined as ≥2 and non-frequent
exacerbation < 2.
Results: Patients with COPD had reduced DPA and exercise capacity compared with controls similar in age, BMI
and gender, p < 0.001. Frequent exacerbators had less DPA than infrequent exacerbators and both less than
controls, p < 0.001. Patients with higher BODE index were less active than those with lower index. Time spent on
moderate activity was related to cardiovascular risk factors including arterial stiffness. The DPA in patients was
independent of age, gender, spirometry, body composition and HGS, p > 0.05. The level of breathlessness was
superior to lung function in predicting the level of DPA.
Conclusion: The level of DPA in COPD was independent of traditional risk factors. Breathlessness score is a better
predictor of the DPA than lung function and handgrip strength.
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Background
Reduced daily physical activity (DPA) is a multifactorial def-
icit in chronic obstructive pulmonary disease [1]. Reduced
DPA is a key contributor to cardiovascular morbidity, re-
current hospital admissions related to exacerbations, dis-
ease progression and reduced health related quality of life
[2]. Physical inactivity is also the strongest predictor for all-
cause mortality in this population [3]. Nevertheless, it is
modifiable and studies indicate that engaging in a regular
physical activity could reduce the risk of cardiovascular dis-
ease, hospitalisation rate and death related to COPD [4, 5].
Garcia-Aymerich and colleagues found that participation in
physical activity equivalent to walking or cycling for at least
2 h a week was associated with a 30–40% reduction in the
risk of COPD related hospital admission and mortality [5].
A number of studies have tried to identify factors re-
lated to declining of physical activity in COPD and
yielded controversial results [6–8]. Most common risk
factors reported in these studies are reduced lung func-
tion, musculoskeletal strength, breathlessness score and
inflammation. The discrepancies in the results may be
attributed to the methodological variations as the
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patients recruited in these studies were either partici-
pating in an inpatient or outpatient rehabilitation pro-
gram which may not represent typical patients with
COPD. Patients with COPD are usually referred to
rehabilitation program when they report significant
breathlessness and may be physically inactive and
deconditioned. This may not reflect the general, less
symptomatic COPD population, who may remain ac-
tive and have a reasonable health status. Moreover,
the control subjects recruited in these studies were
relatively active and may not be representative of the
older population.
Therefore, we hypothesised that decreased DPA in
stable community patients with COPD would be inde-
pendent of traditional risk factors.
Methods
Subjects
This is a cross sectional analysis from a large prospective
longitudinal study in COPD (The ARCADE study, Clin-
ical Trials No NCT 01656421) [9]. A convenience sam-
ple of 93 patients with COPD confirmed with post
bronchodilator spirometry and 42 controls, either
current or ex-smokers free from respiratory disease were
recruited.
All patients were clinically stable and had not had any
oral corticosteroids or antibiotics 4 weeks prior to re-
cruitment. Patients were excluded if they were known
with inflammatory disease such as rheumatoid arthritis,
had oral maintenance corticosteroids and long-term oxy-
gen therapy or had attended pulmonary rehabilitation.
Participants were recruited from respiratory outpatient
clinics, smoking cessation referrals and general practice
databases. Controls were recruited from general practice
databases, smoking cessation clinic and patients’ rela-
tives. All participants gave written informed consent and
the study had approval from the South East Wales Re-
search Ethics Committee.
Anthropometry and body composition measurement
In all participants, height and weight was measured
barefoot with subjects wearing lightweight clothing and
body composition was assesed using a single frequency
segmental bioelectrical impedance analyser (BC-418
MA, Tanita Corp., Tokyo, Japan). Body mass index (BMI
kg/m2), the fat free mass and fat mass were also deter-
mined. Waist and hip circumference were measured
with a stretch resistant tape [10].
Lung function and COPD related questionnaires
All participants performed spirometry (Vitalograph
alpha, Bucks, UK) to measure the forced expiratory
volume in 1 s (FEV1), the forced vital capacity (FVC)
and FEV1/FVC ratio. Patients were given 400 μg of
salbutamol via a spacer device and repeated the test
10 min post bronchodilator. Patients were asked to
abstain using their inhalers for at least 6 h prior to
their visit [11] .
Breathlessness was scored using the modified Medical
Research Council (MRC) dyspnoea scale. The number of
exacerbations in the last year (defined as requirement
for antibiotic or oral corticosteroid therapy per year)
were recorded. Patients and controls reported also the
number of previously diagnosed comorbidities. Infre-
quent exacerbators were defined as < 2 in the previous
year, while frequent exacerbators as ≥2 [12].
Patients completed the St George’s Respiratory Ques-
tionnaire (SGRQ) and the COPD assessment test (CAT),
both validated measures of health status and symptoms
[13, 14].
Daily physical activity assessment
Participants were given a physical activity monitor (Sen-
seWear™ BodyMedia, Inc. Pittsburgh, PA) on the day of
their visit to Wales Heart Research Institute and asked
to return the monitor after a week from their visit. The
first and last days were excluded from the analysis be-
cause of incomplete measurements of the days. There-
fore, data from 6 days (4 weekdays plus the weekend) of
measurements were available for most participants. Par-
ticipants were asked to wear the monitor the whole day
except during shower or sleep. Wearing time was re-
corded by the monitor. For a valid day of activity meas-
urement, the threshold was set at 16 h of monitor’s
wearing time. Days below that threshold were excluded
from analysis. The monitor has been found to be reliable
and valid in patients with COPD [15]. To avoid seasonal
changes, data were collected from the beginning of May
until the end of September. The variables chosen for this
analysis were the total daily number of steps (Steps) and
daily time spent in at least moderate physical activity as
defined by any activity ≥3 METs. Step count was divided
to above or below 5000 steps/day as a cut-off value of
recommended steps per day [16].
Physical performance
The 6MWD was performed once according to the
American Thoracic Society (ATS) guideline using a 30-
m level, straight indoor track [17]. Maximal handgrip
strength (HGS) was determined twice in each hand and
the mean was calculated for each one using a hand
dynamometer (T.K.K. 5401 grip-D, Takei, Japan).
BODE index
BODE index score was calculated by adding the score of
each variable (BMI, post bronchodilator FEV1, mMRC
and 6MWD).
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Aortic pulse wave velocity
Peripheral systolic and diastolic BP was measured after
10 min rest in seated and supine positions (OMRON
Corporation, Kyoto, Japan). Aortic PWV and central
blood pressures including mean arterial pressure (MAP)
measured noninvasively using SphygmoCor device
(AtCor Medical, Sydney, Australia) [18].
Inflammatory biomarkers
High sensitivity C – reactive protein (HsCRP) and fi-
brinogen were determined by standard assays (Biochem-
istry, University Hospital of Wales).
Statistical analysis
All statistical analysis was performed using the statistical
software package 23.0 (Chicago, Illinois, U.S.A.). Data
were checked for normality prior to analysis. Data were
presented as mean and standard deviation or median
and interquartile range (IQR). Between groups compari-
sons were performed using analysis of variance. Categor-
ical data was analysed using the Chi-square test.
Correlations between variables were explored using
Pearson’s and Spearman correlation coefficients. Multi-
variate analysis was performed using a stepwise multiple
regression model. For all analysis p < 0.05 was consid-
ered significant.
Results
Eighty-eight patients and forty controls had complete
data (Fig. 1). Five patients and two controls were re-
moved from the analysis. Two patients and two controls
did not wear the monitor for seven days and therefore
were excluded. Three patients returned the monitor
after 14 days and the batteries of the monitors were dead
and we could not retrieve the data after charging the
monitors. The patients and controls were similar in age,
gender proportion and BMI. The patients had poorer
lung function (FEV1, FVC and their ratio), lower resting
oxygen saturations and greater tobacco exposure than
the control group (all p < 0.001) (Table 1). The severity
of airflow obstruction by GOLD stratification (Table 2).
The distribution of the modified MRC breathlessness
score was: mMRC 0 n = 11, mMRC 1 n = 34, mMRC 2 =
17, mMRC 3 n = 18 and mMRC 4 n = 8. The patients
were also classified according to GOLD quadrants based
on CAT score (Table 2).
Measures of daily physical activity
The DPA was lower in the patients, mean (SD), 4095
(2720) steps than controls 6734 (3491) steps, p < 0.001,
however, there was no difference in DPA for males and
females in either group, p > 0.05. The DPA was not re-
lated to age in either patients or controls. Using the
minimum recommended level of DPA of 5000 steps/day,
only 31% of the patients had reached the recommended
amount of physical activity; while in contrast, 73% of the
controls met the minimum amount of the DPA.
The DPA related to FEV1% predicted (r = 0.39, p < 0.001),
oxygen saturation (rs = 0.29, p = 0.012) and mMRC dys-
pnoea score (r = −0.45, p < 0.001), in the patients. Only was
FEV1% predicted related to DPA in the controls, r = 0.39,
p = 0.017.
Fig. 1 Consort Diagram
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Daily physical activity and disease severity
Level of DPA differed across the GOLD categories, be-
tween GOLD 1 and GOLD 4, p = 0.004 (Fig. 2). Patients
with an FEV1 > 50% had greater level of DPA, lower ex-
acerbation rate, breathlessness score and CAT score than
patients with an FEV1 < 50%, p < 0.001. There was an asso-
ciation between level of DPA and BODE index, p < 0.001.
Patients with BODE score of ≥6 walked less significantly
than patients with a lower score, p < 0.001 (Fig. 3).
Daily physical activity and body composition and physical
function
There was no relationship between body composition
parameters and DPA in the patients or control group.
However, in the patients, the time spent undertaking
moderate activity was related to BMI, r = − 0.39, FM, r =
− 0.37, FFM:FM, r = 0.50, all p < 0.001. Similar relation-
ships were evident in the control group, all p < 0.05.
The 6MWD and HGS were less in patients than con-
trols, both p < 0.001 (Table 1). In the patients, the level
of daily of daily physical activity was related to the
6MWD, r = 0.45, p = 0.001, and controls, r = 0.49, p =
0.002, but it was not related to HGS, p > 0.05. The
6MWD and HGS were all related to each other in the
patients, p < 0.01.
Daily physical activity and aortic stiffness
In the patients, the time spent undertaking moderate ac-
tivity was related to aortic stiffness (rs = − 0.28, p < 0.01),
resting oxygen saturation (rs = − 0.38, p < 0.002). This
was not evident in controls. Aortic stiffness was greater
in patients, 9.5 (2.2), than controls, 8.2 (1.4),p < 0.01.
Patient reported outcomes
The level of DPA and the SGRQ total score were related
(r = − 0.38, p < 0.001), as was the SGRQ activity domain
(r = − 0.40, p < 0.001). The CAT score was also related to
the level DPA (r = − 0.34, p = 0.003). The 6MWD also re-
lated to the total SGRQ score, r = − 0.63, and the CAT
score r = − 0.54, (all p < 0.001).
Of the patients, 41 reported 0–1 exacerbations/ year
and 47 reported two or more exacerbations/ year. The
level of DPA was related to the frequency of exacerba-
tions r = − 0.34, p < 0.001, and frequent exacerbators,
3348 (2221) steps, had lower physical activity of daily liv-
ing than infrequent exacerbators, 5094 (3027) steps.
Systemic inflammation
Circulating CRP and fibrinogen were greater in patients
than controls (p < 0.001) and both were related to the
level of DPA, CRP, rs = − 0.29, p = 0.013, and fibrinogen,
r = − 0.30, p = 0.009, but were unrelated to the level of
DPA in the control group.
Predictive factors for the daily physical activity
In the patients, a stepwise multivariate regression ana-
lysis including DPA as a dependent variable and FEV1%,
mMRC and the number of exacerbations as the inde-
pendent variables showed that mMRC and number of
exacerbations explained 28% of the variability in the
DPA with FEV1% predicted excluded from the analysis,
Table 1 Physical and Clinical Characteristics of patients with
COPD and Controls
COPD (n = 88) Comparator
(n = 40)
p
Gender Male: female 46:42 19:21 0.117
Age (years) 66 (8) 66 (7) 0.923
Smoking (pack years) 42.2 (24.8) 22.9 (20.8) 0.001
FEV1 (L) 1.5 (0.8) 2.6 (0.6) 0.001
FVC (L) 2.4 (0.9) 3.4 (0.9) 0.001
FEV1/FVC 0.52 (0.1) 0.78 (0.05) 0.001
FEV1 (%) 56 (17) 106 (17) 0.001
FVC (%) 84 (19) 112 (17) 0.001
Resting O2 saturation (%) 96 (2) 98 (1) 0.001
BMI (kg/m2) 27.5 (5.2) 28.6 (4.9) 0.297
Waist:Hip ratio 0.95 (0.09) 0.89 (0.06) 0.002
FFM (kg) 49.5 (10.5) 50.9 (9.1) 0.486
FM (kg) 24.8 (9.9) 27.2 (10.3) 0.243
FFM/FM 2.3 (1.1) 2.2 (1.1) 0.556
FFMI (kg/m2) 18.2 (2.4) 18.5 (2.1) 0.589
FMI (kg/m2) 9.3 (3.9) 10.1 (4.3) 0.3
6MWD (m) 336 (107) 515 (88) 0.001
Mean handgrip (kg) 27.2 (9.6) 29.7 (10.2) 0.209
Fibrinogen (g/l) # 3.8 (1.3) 3.2 (0.6) 0.012
HsCRP (mg/l)# 3.3 (3.1) 1.6 (3.2) 0.023
No. Steps 4095 (2720) 6734 (3491) 0.001
Time spent on moderate
activity (hr)*
1.3 (0.5–2.2) 1.3 (0.7–2.1) 0.662
No. Comorbidity 1.3 (1.2) 0.8 (0.8) 0.027
All data mean (SD) unless otherwise indicated *Median (range) # Geometric
mean. Abbreviations: 6MWD six minute walk distance, BMI body mass index,
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, FFM fat free
mass, FFMI fat free mass index, FM fat mass, FMI fat mass index, HsCRP high
sensitivity C- reactive protein.
Table 2 Distribution of Patients with COPD according to GOLD
classifications and Quadrants
GOLD Classification Patients Number GOLD Quadrants Patients
Number
GOLD I 9 GOLD A 8
GOLD II 50 GOLD B 24
GOLD III 25 GOLD C 10
GOLD IV 4 GOLD D 46
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adjusted R2 = 0.28,p < 0.001. The mMRC and the number
of exacerbations explained 34 and 25% of the reduction
in the DPA, respectively.
Discussion
To our knowledge, this is the first study to comprehen-
sively examine risk factors associated with daily physical
activity in stable community patients with COPD and
controls similar in age and gender. The DPA in COPD
was associated with level of breathlessness and frequency
of exacerbations, independent of age, lung function, sex,
peripheral muscle mass strength.
The GOLD classification was not discriminative
enough between patients with moderate and severe im-
paired DPA. The level of breathlessness was found to be
superior to lung function. This may be explained as a
number of studies have found that FEV1 is less sensitive
to describe the complexity of COPD and weakly related
to the level of breathlessness [19, 20]. Breathlessness is
the most common reason for visiting primary care and
respiratory physicians regardless the severity of lung
function [21]. A recent study on patients attending pri-
mary care found physical inactivity was associated with
breathlessness independent of lung function [22]. Per-
ception of breathlessness, which patients experience dur-
ing performing DPA, is involved in a complex
mechanism beyond respiratory mechanical factors [23].
Patients with severe breathlessness often limit their DPA
to minimise dyspnoea and creating a vicious cycle of in-
activity, muscle atrophy, deconditioning and which re-
sult in greater activity intolerance [15, 24–27]. Similar
findings reported by other researchers confirming the in-
dependent relationship between disease severity and
DPA [8, 28].
Patients with poor prognosis (BODE ≥6) had limited
DPA which is a strong predictor of poor outcomes
Fig. 2 Daily physical activity disease severity (GOLD categories). Bars represent means and vertical lines represent upper and lower 95%
confidence intervals for each category
Fig. 3 Daily Physical activity and BODE index<or > 6. Bars represent means and vertical lines represent upper and lower 95% confidence intervals
for each category
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including mortality [29, 30]. Similarly, a number of stud-
ies reported in a small cohort study in patients with
COPD a direct relationship between physical inactivity
and increased BODE index [24, 31]. This is supported by
the concept that reduced DPA is a strong predictor of
morbidity and mortality in patients with COPD [3, 5].
Pitta and colleagues found inactivity for just one day
doubled the BODE score, which increased the probabil-
ity of premature mortality [24]. BODE index is a multi-
dimensional and appears to have the capacity to stratify
patients better than a single marker of airway severity, as
FEV1 cannot reflects the whole picture of COPD.
Reduced DPA increases the risk of cardiovascular dis-
ease and its related risk factors including arterial stiff-
ness. Arterial stiffness is a validated marker of CV
morbidity and mortality. A few studies have examined
the relationship between DPA and arterial stiffness in
COPD and showed different results [32, 33]. In our
study, moderate DPA was associated with reduced arter-
ial stiffness. Increased arterial stiffness is a surrogate
marker of increased risk of cardiovascular disease in
COPD, which could be reduced by increasing DPA [34–
37]. Indeed, a number of studies found a reduction in
aortic stiffness after patients with COPD attended a
structured programme of pulmonary rehabilitation [37,
38]. A recent study found that patients engaging in any
type of moderate physical activity was associated with
lower mortality rate after one year compared to inactive
patients [39].
Altered body composition is an accepted feature of
COPD with several studies reporting reduced musculo-
skeletal mass and strength [40–43]. However, in our
study, neither muscle mass nor HGS was associated with
reduced DPA and exercise capacity. Van Gestel and col-
leagues reported a similar finding to our study and
showed that HGS was not associated with DPA and
could not be used to predict DPA [44]. A possible
explanation is that despite the limitations of lower limb
activities by breathlessness, upper limb activities and
strength may be maintained [1].
In addition, the larger lower limb mass may be more
affected by circulating inflammation, a key feature of
COPD. Increased circulatory inflammation may pro-
foundly alter musculoskeletal function, increase muscle
oxidative stress and accelerate muscle protein degrad-
ation [21, 45]. Systemic inflammation (CRP) was ele-
vated in COPD in the present study and was associated
with fat mass a potential source of inflammation and im-
paired DPA. Increased inflammatory biomarkers i.e.
CRP and fibrinogen, which are associated with increased
risk of cardiovascular disease and insulin resistance, and
their association with reduced DPA has been previously
shown in individuals with COPD and community
dwellers [46, 47]. Increased systemic inflammation (SI) is
linked to an exacerbation frequency, which is associated
with breathlessness and impaired DPA [46].
Limitations
A key limitation of this study is its cross-sectional na-
ture, and this issue is being addressed in the ongoing
longitudinal ARCADE study. We had a limited number
of DPA monitors so which curtailed recruitment.
Conclusion
The increased level of breathlessness and frequency of
exacerbation are key factors in limiting daily physical ac-
tivity in patients with COPD independent of loss of
muscle mass and strength. The association between re-
duced DPA and breathlessness suggests that interven-
tions to improve perception of breathlessness may
optimise patient outcomes including physical activity.
There is a need for long-term behavioural interventions
to increase/maintain DPA in patients with COPD.
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